Cardiac Sarcoidosis: A Comprehensive Clinical Review
Authors:
Open Access
- 29 January 2024
- journal article
- review article
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (2) , 37
Abstract
Sarcoidosis is an inflammatory multisystemic disease of unknown etiology characterized by the formation of non-caseating granulomas. Sarcoidosis can affect any organ, predominantly the lungs, lymphatic system, skin and eyes. While >90% of patients with sarcoidosis have lung involvement, an estimated 5% of patients with sarcoidosis have clinically manifest cardiac sarcoidosis (CS), whereas approximately 25% have asymptomatic, clinically silent cardiac involvement verified by autopsy or imaging studies. CS can present with conduction disturbances, ventricular arrhythmias, heart failure or sudden cardiac death. Approximately 30% of <60-year-old patients presenting with unexplained high degree atrioventricular (AV) block or ventricular tachycardia are diagnosed with CS, therefore CS should be strongly considered in such patients. CS is the second leading cause of death among patients affected by sarcoidosis after pulmonary sarcoidosis, therefore its early recognition is important, because early treatment may prevent death from cardiovascular involvement. The establishment of isolated CS diagnosis sometimes can be quite difficult, when extracardiac disease cannot be verified. The other reason for the difficulty to diagnose CS is that CS is a chameleon of cardiology and it can mimic (completely or almost completely) different cardiac diseases, such as arrhythmogenic cardiomyopathy, giant cell myocarditis, dilated, restrictive and hypertrophic cardiomyopathies. In this review article we will discuss the current diagnosis and management of CS and delineate the potential difficulties and pitfalls of establishing the diagnosis in atypical cases of isolated CS.Keywords
This publication has 118 references indexed in Scilit:
- FDG uptake patterns in isolated and systemic cardiac sarcoidosisJournal of Nuclear Cardiology, 2022
- Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosisJournal of Nuclear Cardiology, 2022
- Cardiac Sarcoidosis Completely Mimicking Biventricular Arrhythmogenic CardiomyopathyESC Heart Failure, 2022
- Late Gadolinium Enhancement Characteristics in Giant Cell MyocarditisESC Heart Failure, 2021
- Idiopathic Giant Cell Myocarditis or Cardiac Sarcoidosis? A Retrospective Audit of a Nationwide Case SeriesESC Heart Failure, 2020
- The Chameleon of Cardiology: Cardiac Sarcoidosis Before and After Heart TransplantationESC Heart Failure, 2019
- Management and Outcomes of Cardiac Sarcoidosis: A 20-Year Experience in Two Tertiary Care CentresEuropean Journal of Heart Failure, 2018
- Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosisJournal of Nuclear Cardiology, 2014
- Idiopathic giant cell myocarditis and cardiac sarcoidosisHeart Failure Reviews, 2012
- Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosisThe American Journal of Cardiology, 2005